JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.35 -2.78

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.34

Máximo

0.36

Métricas clave
By Trading Economics
Ingresos	983K -47M
Ventas	505K 14M
Margen de beneficios	-342.329
Empleados	161
EBITDA	-346K -46M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+1089.19% upside

Dividendos
By Dow Jones
Próximas Ganancias	14 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-24M 82M
Apertura anterior	3.13
Cierre anterior	0.35

Noticias sobre sentimiento de mercado

By Acuity

71%

29%

320 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 may 2026, 21:36 UTC

Adquisiciones, fusiones, absorciones

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 may 2026, 20:40 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 may 2026, 18:37 UTC

Principales Movimientos del Mercado

Senseonic Shares Slide on Underwritten Offering Price

1 may 2026, 16:46 UTC

Principales Movimientos del Mercado

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

1 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 may 2026, 20:42 UTC

Ganancias

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 may 2026, 19:33 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 may 2026, 19:33 UTC

Charlas de Mercado

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 may 2026, 19:18 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 may 2026, 19:13 UTC

Charlas de Mercado

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 may 2026, 18:36 UTC

Ganancias

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 may 2026, 18:35 UTC

Ganancias

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 may 2026, 18:28 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 may 2026, 18:27 UTC

Charlas de Mercado

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 may 2026, 18:14 UTC

Adquisiciones, fusiones, absorciones

Barclays Completes Acquisition of Best Egg

1 may 2026, 18:04 UTC

Ganancias

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 may 2026, 17:43 UTC

Charlas de Mercado

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 may 2026, 17:37 UTC

Charlas de Mercado

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 may 2026, 17:30 UTC

Charlas de Mercado

Ganancias

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 may 2026, 17:28 UTC

Charlas de Mercado

Ganancias

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 may 2026, 17:21 UTC

Charlas de Mercado

Ganancias

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 may 2026, 17:19 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 may 2026, 16:38 UTC

Charlas de Mercado

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 may 2026, 16:23 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

1 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 may 2026, 16:15 UTC

Ganancias

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1 may 2026, 16:11 UTC

Charlas de Mercado

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1 may 2026, 16:04 UTC

Ganancias

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

1089.19% repunte

Estimación a 12 Meses

Media 4.4 USD 1089.19%

Máximo 15 USD

Mínimo 0.3 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

320 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.